The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 535-539

  Shen, Xiaokun ^a   Hong, Lingzhi ^a   Sun, Huiming ^a   Shi, Minke ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

High mobility group protein box 1; Non small cell lung cancer; Progression; Real time PCR

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA;

ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADULT; AGED; CHEMISTRY; DISEASE COURSE; FEMALE; GENETICS; LUNG; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HMGB1 PROTEIN; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER;

EID: 70349303707     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000468     Document Type: Article

References (28)

1. Agresti A and Bianchi ME: HMGB proteins and gene expression. Curr Opin Genet Dev 13: 170-178, 2003.
2. Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
3. Klune JR, Dhupar R, Cardinal J, Billiar TR and Tsung A: HMGB1: endogenous danger signaling. Mol Med 14: 476-484, 2008.
4. Lotze MT, Zeh HJ, Rubartelli A, et al: The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220: 60-81, 2007.
5. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J and Rauvala H: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 266: 16722-16729, 1991.
6. Taguchi A, Blood DC, del Toro G, et al: Blockade of AGER-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
7. Riuzzi F, Sorci G and Donato R: The amphoterin (HMGB1)/receptor for advanced glycation end products (AGER) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of AGER in L6 myoblasts results in tumor formation in vivo. J Biol Chem 281: 8242-8253, 2006.
8. Mitola S, Belleri M, Urbinati C, et al: Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176: 12-15, 2006.
9. Flohr AM, Rogalla P, Meiboom M, et al: Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885, 2001.
10. Brezniceanu ML, Volp K, Bosser S, et al: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17: 1295-1297, 2003.
11. Kawahara N, Tanaka T, Yokomizo A, et al: Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 56: 5330-5333, 1996.
12. Poser I and Bosserhoff AK: Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 19: 173-188, 2004.
13. Poser I, Golob M, Buettner R and Bosserhoff AK: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998, 2003.
14. Choi YR, Kim H, Kang HJ, et al: Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63: 2188-2193, 2003.
15. Meyer A, Staratschek-Jox A, Springwald A, et al: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 49: 1184-1189, 2008.
16. Volp K, Brezniceanu ML, Bosser S, et al: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55: 234-242, 2006.
17. Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059, 2007.
18. Bartling B, Hofmann HS, Weigle B, Silber RE and Simm A: Down-regulation of the receptor for advanced glycation end-products (AGER) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301, 2005.
19. Muller S, Ronfani L and Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343, 2004.
20. Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201, 2006.
21. Ellerman JE, Brown CK, de Vera M, et al: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007.
22. Campana L, Bosurgi L and Rovere-Querini P: HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 20: 518-523, 2008.
23. Akaike H, Kono K, Sugai H, et al: Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27: 449-457, 2007.
24. Wu D, Ding Y, Wang S, Zhang Q and Liu L: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216: 167-175, 2008.
25. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
26. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296-301, 2004.
27. Ulloa L, Ochani M, Yang H, et al: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99: 12351-12356, 2002.
28. Hanford LE, Enghild JJ, Valnickova Z, et al: Purification and characterization of mouse soluble receptor for advanced glycation end products (sAGER). J Biol Chem 279: 50019-50024, 2004.